Showing results (1031-1040 of 1,160) with videos related to

Sort By:
Pageof 116
The Knee|May 30, 2025
The functional outcome and complication rates in tibial plateau fractures: A comparison between three different classification systemsAlejandro Sánchez García, David González Quevedo, Miguel Sáez Casado, et al.
International Journal of Hypertension|November 8, 2022
Mortality in Elderly Patients Taking Furosemide: Prospective Cohorts StudyAlejandro Rodríguez-Molinero, Antonio Miñarro, Leire Narvaiza, et al.
Archives of Dermatological Research|October 31, 2013
MC1R gene variants and sporadic malignant melanoma susceptibility in the Canary Islands populationElizabeth Córdoba-Lanús, José G Hernández-Jiménez, Chaxiraxi Medina-Coello, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|May 18, 2026
Biomarkers and Prognosis After Myocardial Infarction: Towards Precision CardiologySimón Rodríguez-Moar, Carmen Neiro-Rey, David García-Molinero, et al.
Molecular Immunology|June 22, 2011
Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1Marta A Toscano, Leonardo Campagna, Luciana L Molinero, et al.
Epilepsia|December 1, 2020
Seizure control, stress, and access to care during the COVID-19 pandemic in New York City: The patient perspectiveJillian L Rosengard, Jad Donato, Victor Ferastraoaru, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
International Journal of Medical Informatics|April 13, 2011
Innovations in health care services: the CAALYX systemArtur Rocha, Angelo Martins, José Celso Freire Junior, et al.
Science Translational Medicine|February 28, 2014
β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cellsShilpa Keerthivasan, Katayoun Aghajani, Marei Dose, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Pageof 116